Keros Therapeutics (KROS) to Release Quarterly Earnings on Wednesday

Keros Therapeutics (NASDAQ:KROS - Get Free Report) is projected to post its quarterly earnings results before the market opens on Wednesday, February 26th. Analysts expect Keros Therapeutics to post earnings of ($1.36) per share and revenue of $37.32 million for the quarter.

Keros Therapeutics Price Performance

Shares of NASDAQ KROS traded down $0.03 during mid-day trading on Friday, hitting $11.01. The company had a trading volume of 896,681 shares, compared to its average volume of 1,672,246. The business's 50-day simple moving average is $13.35 and its 200-day simple moving average is $41.02. Keros Therapeutics has a 12 month low of $9.77 and a 12 month high of $73.00. The firm has a market cap of $445.81 million, a P/E ratio of -2.11 and a beta of 1.39.

Wall Street Analysts Forecast Growth

KROS has been the subject of several research reports. William Blair cut shares of Keros Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Thursday, December 12th. BTIG Research cut shares of Keros Therapeutics from a "buy" rating to a "neutral" rating in a research note on Thursday, December 12th. Cantor Fitzgerald lowered shares of Keros Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Tuesday, January 21st. HC Wainwright dropped their price target on shares of Keros Therapeutics from $100.00 to $47.00 and set a "buy" rating for the company in a research report on Friday, December 13th. Finally, Truist Financial dropped their price target on shares of Keros Therapeutics from $100.00 to $43.00 and set a "buy" rating for the company in a research report on Monday, December 23rd. Six analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $52.56.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.